New combo aims to outsmart Treatment-Resistant colorectal cancer
Disease control
Recruiting now
This study tests a new drug combination for people with advanced colorectal cancer that has not responded to standard treatments. The experimental drug isunakinra is added to the immunotherapy pembrolizumab to try to make the cancer more responsive. About 20 adults with a specifi…
Phase: PHASE2 • Sponsor: Buzzard Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:22 UTC